Invitrogen Begins Global Distribution of Custom Oligonucleotides
News Dec 01, 2005
Invitrogen Corporation has announced the introduction of tube-based oligos at the 25nmole starting synthesis scale.
Invitrogen claims that, the tube-based offerings deliver significant value to the life science market, enabling researchers to effectively procure twice as much quantity of high-quality primers for the same competitive price they were previously paying for tube-based oligos synthesized at the 10nmole starting synthesis scale.
This scale change is a further outcome of the collaboration with Illumina. Invitrogen Corporation and Illumina, Inc. are collaborating to manufacture, sell, and support oligo products in both plates and tubes to researchers worldwide.
Coupled with Invitrogen's global distribution and customer support, Illumina's oligo manufacturing technology is designed to provide a broad array of superior quality oligonucleotide products and services.
Invitrogen and Illumina announced in December 2004 a strategic alliance to combine their DNA synthesis, distribution and marketing capabilities.
"This collaboration has allowed Invitrogen to create a fully automated synthesis system by applying state of the art technology for plates and tubes," said Nicolas Barthelemy, Invitrogen Senior Vice President, Operations.
"Combined with our world-class customer service and technical support, we are providing increased value to researchers by offering superior oligos at very competitive prices."
The Invitrogen and Illumina custom DNA oligo production processes are driven by Illumina's proprietary synthesis platform.
In addition to synthesis capabilities, Illumina's automated manufacturing process results in accuracy and efficiency from order entry to documentation and shipping.
Invitrogen and Illumina have coordinated respective enterprise IT systems to integrate oligo ordering, synthesis and distribution.
"As a part of our collaboration, we have significantly expanded synthesis capacity, post-processing infrastructure, and automated order management," said John Stuelpnagel, Illumina Senior Vice President and COO.
"Our customers will benefit from the increased range and availability of products brought about by these efforts."
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE